Arecor collaborates with pharmaceutical and biotech companies who are developing recombinant proteins and vaccines for application in drugs, medical devices or diagnostics. Arecor has developed Arestat™, a smart stabilization technology, which enables the formulation of labile proteins and vaccines as stable aqueous or dry preparations even at high concentrations or in the presence of ionizing radiation. As a simple reformulation, the technology can be readily integrated into existing manufacturing processes. Arestat™ does not involve the covalent modification of biologics and uses only GRAS (Generally Regarded As Safe) excipients approved by relevant regulatory authorities. Arecor is a spin out of Unilever Research and Unilever Ventures is our lead investor.